Moderna (MRNA) fundamentals: P/E, valuation, undervalued?
Moderna · Health Care · ref. ETF XLV · price $216.25
In short — Moderna trades at —× earnings (P/E), -48.7× forward, with a net margin of -141.4 % and revenue growth of +2 %. Read: Not (yet) profitable (valued on growth, not earnings).
Is Moderna stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$216.25+723.8% over range
Oct 14, 25low $22.36 · high $225Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
21% recommend buying · 14 analysts
Valuation : Not (yet) profitable — valued on growth, not earnings
Valuation
—
P/E (price/earnings)
-48.7
Forward P/E
—
PEG
12.8
Price/book (P/B)
$86.3B
Market cap
-7.98
EPS
Profitability & growth
-141.4 %
Net margin
+2 %
Revenue growth
—
Earnings growth
$1.3B
Total debt
Moderna income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $19.3B | $8.4B | 43.4 % |
| 2023 | $6.8B | $-4.7B | -68.8 % |
| 2024 | $3.2B | $-3.6B | -110.0 % |
| 2025 | $1.9B | $-2.8B | -145.2 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Moderna's P/E and is the stock undervalued? What's a good P/E?
Moderna's P/E is — (forward -48.7). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Not (yet) profitable".
Is Moderna profitable?
Moderna has a net margin of -141.4 % (EPS -7.98). The company is not (yet) profitable.
Is MRNA stock expensive?
Our read: "Not (yet) profitable" — valued on growth, not earnings. Cross-check with growth and sector.
💬 A question about Moderna? The JPI assistant answers using our backtest data.